Archiv der Pharmazie · 2019 · 21 citations · 38 references
PharmacyMedicinal ChemistryPharmacologyDrug DesignDrug DiscoveryStructure-activity RelationshipsEnzyme InhibitionHit-to-lead OptimizationLead Compound DesignLead DiscoveryStructure-activity Relationship AnalysisAnticancer Compound ScreeningChemical Synthesis Of AnaloguesLead Compound ScreeningMedicinal Chemistry ApplicationsPharmacological ScreeningThiazole Chemistry
Abstract The antioxidant, antimalarial, antibacterial, and antitumor activities of thiosemicarbazones have made this class of compounds important for medicinal chemists. In addition, thiosemicarbazones are among the most potent and well‐known ribonucleotide reductase inhibitors. In this study, 24 new thiosemicarbazone derivatives were synthesized, and the structures and purity of the compounds were determined by IR, 1 H NMR, 13 C NMR, mass spectroscopy, and elemental analysis. The IC 50 values of these 24 compounds were determined with an assay for ribonucleotide reductase inhibition. Compounds 19, 20 , and 24 inhibited ribonucleotide reductase enzyme activity at a higher level than metisazone as standard. The cytotoxic effects of these compounds were measured on the MCF7 (human breast adenocarcinoma) and HEK293 (human embryonic kidney) cell lines. Similarly, compounds 19, 20 , and 24 had a selective effect on the MCF7 and HEK293 cell lines, killing more cancer cells than cisplatin as standard. The compounds (especially 19, 20 , and 24 as the most active ones) were then subjected to docking experiments to identify the probable interactions between the ligands and the enzyme active site. The complex formation was shown qualitatively. The ADME (absorption, distribution, metabolism, and excretion) properties of the compounds were analyzed using in‐silico techniques.
38
Sohail Saeed, Naghmana Rashid, Peter G. Jones et al. · European Journal of Medicinal Chemistry · 2009 · 429 citations
Ribonucleotide Reductase—a Radical Enzyme
Peter Reichard, Anders Ehrenberg · Science · 1983 · 425 citations